These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 18416173)

  • 21. The effect of diet on simvastatin and losartan enhancement of endothelial function.
    Bayorh MA; Layas MF; Mann G; Feuerstein GZ; Eatman D
    Clin Exp Hypertens; 2007 Jul; 29(5):311-25. PubMed ID: 17653966
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design of the heart failure endpoint evaluation of AII-antagonist losartan (HEAAL) study in patients intolerant to ACE-inhibitor.
    Konstam MA; Poole-Wilson PA; Dickstein K; Drexler H; Justice SJ; Komajda M; Malbecq W; Martinez FA; Neaton JD; Riegger GA; Guptha S
    Eur J Heart Fail; 2008 Sep; 10(9):899-906. PubMed ID: 18768350
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical usefulness of the angiotensin II receptor antagonist losartan in patients with portal hypertensive gastropathy.
    Wagatsuma Y; Naritaka Y; Shimakawa T; Kanako H; Keiichiro I; Shunichi S; Konno S; Katsube T; Ogawa K
    Hepatogastroenterology; 2006; 53(68):171-4. PubMed ID: 16608017
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of the angiotensin II receptor blocker losartan on the monocyte expression of biglycan in hypertensive patients.
    Sardo MA; Mandraffino G; Riggio S; D'Ascola A; Alibrandi A; Saitta C; Imbalzano E; Castaldo M; Cinquegrani M; Saitta A
    Clin Exp Pharmacol Physiol; 2010 Sep; 37(9):933-8. PubMed ID: 20497421
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of losartan, compared with atenolol, on endothelial function and oxidative stress in patients with type 2 diabetes and hypertension.
    Flammer AJ; Hermann F; Wiesli P; Schwegler B; Chenevard R; Hürlimann D; Sudano I; Gay S; Neidhart M; Riesen W; Ruschitzka F; Lüscher TF; Noll G; Lehmann R
    J Hypertens; 2007 Apr; 25(4):785-91. PubMed ID: 17351370
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protective mechanisms of the angiotensin II type 1 receptor blocker candesartan against cerebral ischemia: in-vivo and in-vitro studies.
    Liu H; Kitazato KT; Uno M; Yagi K; Kanematsu Y; Tamura T; Tada Y; Kinouchi T; Nagahiro S
    J Hypertens; 2008 Jul; 26(7):1435-45. PubMed ID: 18551021
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of simvastatin on the antihypertensive activity of losartan in hypertensive hypercholesterolemic animals and patients: role of nitric oxide, oxidative stress, and high-sensitivity C-reactive protein.
    Abdel-Zaher AO; Elkoussi AE; Abudahab LH; Elbakry MH; Elsayed EA
    Fundam Clin Pharmacol; 2014 Jun; 28(3):237-48. PubMed ID: 23488690
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of angiotensin II type 1 (AT1) receptor antagonist on the endothelial dysfunction in spontaneously hypertensive rats in correlation with the nitric oxide system.
    Slaninka-Miceska M; Bogdanska J; Korneti P; Kostova E; Jovanoska E; Petrov S
    Bratisl Lek Listy; 2003; 104(11):342-6. PubMed ID: 15055718
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment with low-dose atorvastatin, losartan, and their combination increases expression of vasoactive-related genes in rat aortas.
    Lunder M; Drevenšek G; Černe D; Marc J; Janić M; Šabovič M
    J Cardiovasc Pharmacol Ther; 2013 Mar; 18(2):177-83. PubMed ID: 23091284
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of the angiotensin receptor antagonist losartan on the response of the left main coronary artery to cold pressor test in patients with essential hypertension as assessed by echocardiography.
    Deng YB; Wang DW; Li CL; Yang HY
    Can J Cardiol; 2002 Apr; 18(4):389-96. PubMed ID: 11992132
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trial.
    Axelsson A; Iversen K; Vejlstrup N; Ho C; Norsk J; Langhoff L; Ahtarovski K; Corell P; Havndrup O; Jensen M; Bundgaard H
    Lancet Diabetes Endocrinol; 2015 Feb; 3(2):123-31. PubMed ID: 25533774
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of vasculoprotective effects of benidipine and losartan in a rat model of metabolic syndrome.
    Matsuzaki G; Ishizaka N; Furuta K; Hongo M; Saito K; Sakurai R; Koike K; Nagai R
    Eur J Pharmacol; 2008 Jun; 587(1-3):237-42. PubMed ID: 18457832
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of nitric oxide-producing and -degrading pathways in coronary endothelial dysfunction in chronic kidney disease.
    Tatematsu S; Wakino S; Kanda T; Homma K; Yoshioka K; Hasegawa K; Sugano N; Kimoto M; Saruta T; Hayashi K
    J Am Soc Nephrol; 2007 Mar; 18(3):741-9. PubMed ID: 17267746
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination therapy with losartan and L-carnitine protects against endothelial dysfunction of streptozotocin-induced diabetic rats.
    Sleem M; Taye A; El-Moselhy MA; Mangoura SA
    Eur J Pharmacol; 2014 Dec; 744():10-7. PubMed ID: 25281836
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of the angiotensin II receptor antagonist, losartan, on myocardial fibrosis in patients with end-stage renal disease: assessment by ultrasonic integrated backscatter and biochemical markers.
    Shibasaki Y; Nishiue T; Masaki H; Tamura K; Matsumoto N; Mori Y; Nishikawa M; Matsubara H; Iwasaka T
    Hypertens Res; 2005 Oct; 28(10):787-95. PubMed ID: 16471172
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Telmisartan protects against vascular dysfunction with peroxisome proliferator-activated receptor-γ activation in hypertensive 5/6 nephrectomized rats.
    Toba H; Wang J; Ohigashi M; Kobara M; Nakata T
    Pharmacology; 2013; 92(5-6):265-75. PubMed ID: 24281041
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients.
    Koh KK; Quon MJ; Han SH; Chung WJ; Ahn JY; Seo YH; Kang MH; Ahn TH; Choi IS; Shin EK
    Circulation; 2004 Dec; 110(24):3687-92. PubMed ID: 15569835
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of the effect of enalapril and losartan in conjunction with surgical coronary revascularisation versus revascularisation alone on systemic endothelial function.
    Trevelyan J; Needham EW; Morris A; Mattu RK
    Heart; 2005 Aug; 91(8):1053-7. PubMed ID: 16020596
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Comparative characteristic of angiotensin-converting enzyme inhibitor--captopril and the angiotensin II receptor blokers--losartan action on the oxidative metabolism in experimental hyperlipidemia in rabbits].
    Antelava NA; Gongadze NV; Gogolauri MI; Kezeli TD; Pachkoriia KZ
    Georgian Med News; 2007 Sep; (150):57-60. PubMed ID: 17984566
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.